You are here

High Z Oraya Therapy for wet AMD

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41EY024197-01
Agency Tracking Number: R41EY024197
Amount: $215,200.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NEI
Solicitation Number: PA13-089
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
NEWARK, CA 94560-1154
United States
DUNS: 800217684
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (510) 456-3708
Business Contact
Phone: (510) 456-3708
Research Institution
450 Brookline Avenue
BOSTON, MA 02215-5450
United States

 () -
 Domestic Nonprofit Research Organization

Project Description The purpose of this project is to develop a new radiotherapy treatment modality that will substantially enhance the treatment of wet AMD with minimal toxicity to healthy tissue, leading to major improvement in visual acuity, decreaseduse of intravitreal injections of anti-VEGF agents, lower cost of treatment, and a substantially improved quality of life for patients. The new modality entitled Customizable Radiotherapy Enhancement (CuRE) using gold nanoparticles will enable major highly localized amplification of radiation damage to the neovascular AMD disease cells with minimal normal ocular tissue toxicity. In order to accomplish this, a potent amount of gold nanoparticles (AuNP), acting as smart bombs will be targeted specificallyto the neovascular AMD (disease) endothelial cells (ECs) as demonstrated in published simulations by Harvard Medical School project partner. Once the AuNP home on to the disease ECs, a relatively small amount of radiation will be focused on the AuNP. The

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government